{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:31:47Z","timestamp":1748449907224},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"03","funder":[{"name":"Health and Labor Sciences Research Grant and Grant-in-Aid for Scientific Research","award":["19K08082"],"award-info":[{"award-number":["19K08082"]}]},{"name":"Health and Labor Sciences Research","award":["H29-seishin-ippan-001"],"award-info":[{"award-number":["H29-seishin-ippan-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIntroduction The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics.<\/jats:p><jats:p>\nMethods The systematic review included 6-week, double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with acute schizophrenia. Pooled data for patients receiving BLO-P 40 and 80\u2009mg\/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20\u2009mg\/day (ASE10+20) and data for those receiving brexpiprazole 2\u2009mg\/day (BRE2) and paliperidone extended-release 6\u2009mg\/day (PAL-ER6).<\/jats:p><jats:p>\nResults All the investigated treatments were superior to placebo in reducing the Positive and Negative Syndrome Scale (PANSS) total score; the Hedges\u2019 g values (95% confidence interval) for BLO-P40+80, ASE10+20, BRE2, and PAL-ER6 were\u22120.40 (\u22120.58,\u22120.22),\u22120.61 (\u22120.79,\u22120.42),\u22120.33 (\u22120.60,\u22120.07), and\u22120.69 (\u22120.93,\u22120.45), respectively. There were differences among the antipsychotics in the incidence of various individual adverse events.<\/jats:p><jats:p>\nDiscussion BLO-P40+80 may have a good efficacy\/safety\/tolerability profile for the treatment of patients with acute schizophrenia.<\/jats:p>","DOI":"10.1055\/a-1096-1266","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T23:50:17Z","timestamp":1580428217000},"page":"122-132","source":"Crossref","is-referenced-by-count":2,"title":["Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan"],"prefix":"10.1055","volume":"53","author":[{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University, Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiji","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Occupational and Environmental Health Japan, Psychiatry, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University, Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University, Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University, Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,1,30]]},"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1096-1266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:23:22Z","timestamp":1588289002000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1096-1266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":0,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,4,30]]},"published-print":{"date-parts":[[2020,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1096-1266","relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}